Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
18.98
-0.59 (-3.01%)
Dec 20, 2024, 4:00 PM EST - Market closed
Pacira BioSciences Revenue
Pacira BioSciences had revenue of $168.57M in the quarter ending September 30, 2024, with 2.83% growth. This brings the company's revenue in the last twelve months to $694.96M, up 4.40% year-over-year. In the year 2023, Pacira BioSciences had annual revenue of $674.98M with 1.22% growth.
Revenue (ttm)
$694.96M
Revenue Growth
+4.40%
P/S Ratio
1.26
Revenue / Employee
$976,063
Employees
712
Market Cap
876.37M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 674.98M | 8.16M | 1.22% |
Dec 31, 2022 | 666.82M | 125.29M | 23.14% |
Dec 31, 2021 | 541.53M | 111.89M | 26.04% |
Dec 31, 2020 | 429.65M | 8.62M | 2.05% |
Dec 31, 2019 | 421.03M | 83.75M | 24.83% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AMN Healthcare Services | 3.07B |
Adaptive Biotechnologies | 177.28M |
Poseida Therapeutics | 150.86M |
Prothena Corporation | 133.35M |
Zymeworks | 62.20M |
Liquidia | 15.61M |
PCRX News
- 10 days ago - DOMA Perpetual Capital Management Announces Intent to Nominate Four Highly Qualified, Independent Director Candidates at 2025 Annual Meeting of Pacira BioSciences, Inc. - PRNewsWire
- 15 days ago - Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewsWire
- 18 days ago - Pacira Awarded New U.S. Patent Covering EXPAREL Composition - GlobeNewsWire
- 26 days ago - Pacira BioSciences: Not Done Yet Despite Devastating Share Price Losses - Seeking Alpha
- 5 weeks ago - Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee - GlobeNewsWire
- 6 weeks ago - Pacira Biosciences Inc. (PCRX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Pacira BioSciences Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 7 weeks ago - Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024 - GlobeNewsWire